CM

COMPASS Pathways plc

CMPSHealthcareNASDAQ

Medical Care Facilities

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot
MA150+32.67%
$10.02

Price above medium-term moving average.

MA200+45.69%
$9.12

Above long-term trend line.

RSI-14neutral
48.7

Balanced. Not overbought, not oversold.

MACDnegative
-0.1388

Histogram negative, downward momentum.

Financials · Annual
Revenue
$0
Net Income
-$287.9M
-85.6% YoY
EBITDA
-$285.6M
-91.9% YoY
Free Cash Flow
$249.9M

Scan Results

Daily timeframe
DateIndicatorDetails
Sep 3 MACD Negative CrossoverHistogram -0.1211, negative momentum
Sep 2 MACD Negative CrossoverHistogram -0.0821, negative momentum
About COMPASS Pathways plc

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. At a $1.84B market cap, COMPASS Pathways plc ranks as a small-cap company within healthcare. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa.

Where CMPS stands vs its 150-day and 200-day moving averages

As of the September 3, 2026 close, CMPS finished 32.70% above its 150-day moving average ($9.97) and 45.70% above its 200-day moving average ($9.08). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is CMPS overbought or oversold?

At the September 3, 2026 close, CMPS's RSI(14) was 49.4, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$1.84B
Fwd P/E-9.27
EPS$-3.81
Beta2.53
52W Change+159.4%
ROE-319.1%
Analysis

COMPASS Pathways plc holds $433.3M in cash against $54.6M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Annual free cash flow of $249.9M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -319.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.

With a beta above 1.5, CMPS tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, CMPS has financial flexibility that may help navigate uncertain periods. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CMPS.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms